Novo Nordisk A/S/DKr NOVO B
08:00
10:00
12:00
13:55
15:55
1D1W1MYTD1Y5YMAX
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company specializing in diabetes care and hormone replacement therapies. Headquartered in Bagsværd, Denmark, the company is renowned for its insulin and GLP-1 receptor agonists for treating diabetes, as well as products for obesity care and growth hormone therapy. Established in 1923, Novo Nordisk has grown its presence worldwide, operating in numerous countries with a substantial workforce. The company leverages its scientific research capabilities to maintain a strong position in the biopharmaceutical industry, focusing heavily on innovation in chronic disease management. Its integrated supply and production facilities support its strategic emphasis on quality control and sustainable production practices.
Ticker
DKr NOVO B
Sector
Primary listing
CSE
Employees
78,554
Headquarters
Bagsvaerd, Denmark
Website
Novo Nordisk A/S Metrics
BasicAdvanced
kr 1.4T
13.79
kr 23.33
0.35
kr 11.65
3.62%
Price and volume
Market cap
kr 1.4T
Beta
0.35
52-week high
kr 616.50
52-week low
kr 266.90
Average daily volume
7.5M
Dividend rate
kr 11.65
Financial strength
Current ratio
0.776
Quick ratio
0.533
Long term debt to equity
52.491
Total debt to equity
59.574
Dividend payout ratio (TTM)
49.88%
Interest coverage (TTM)
19.21%
Profitability
EBITDA (TTM)
165,493
Gross margin (TTM)
83.44%
Net profit margin (TTM)
32.88%
Operating margin (TTM)
48.69%
Effective tax rate (TTM)
21.33%
Revenue per employee (TTM)
kr 4,020,000
Management effectiveness
Return on assets (TTM)
21.11%
Return on equity (TTM)
71.46%
Valuation
Price to earnings (TTM)
13.787
Price to revenue (TTM)
4.531
Price to book
8.4
Price to tangible book (TTM)
22.54
Price to free cash flow (TTM)
23.462
Free cash flow yield (TTM)
4.26%
Free cash flow per share (TTM)
13.712
Dividend yield (TTM)
3.62%
Growth
Revenue change (TTM)
16.64%
Earnings per share change (TTM)
10.06%
3-year revenue growth (CAGR)
23.59%
10-year revenue growth (CAGR)
11.78%
3-year earnings per share growth (CAGR)
26.29%
10-year earnings per share growth (CAGR)
13.82%
3-year dividend per share growth (CAGR)
27.85%
10-year dividend per share growth (CAGR)
16.64%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk A/S stock?
Novo Nordisk A/S (NOVO B) has a market cap of DKr1.4T as of December 14, 2025.
What is the P/E ratio for Novo Nordisk A/S stock?
The price to earnings (P/E) ratio for Novo Nordisk A/S (NOVO B) stock is 13.79 as of December 14, 2025.
Does Novo Nordisk A/S stock pay dividends?
Yes, the Novo Nordisk A/S (NOVO B) stock pays dividends to shareholders. As of December 14, 2025, the dividend rate is DKr11.65 and the yield is 3.62%. Novo Nordisk A/S has a payout ratio of 49.88% on a trailing twelve-month basis.
When is the next Novo Nordisk A/S dividend payment date?
The next Novo Nordisk A/S (NOVO B) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk A/S?
Novo Nordisk A/S (NOVO B) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.